QT
JNCE

Quantbot Technologies’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Quantbot Technologies’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-561
Closed -$4K – 2180
2021
Q4 		$4K Sell
561
-500
-47% -$4.12K ﹤0.01% 1404
2021
Q3 		$7K Sell
1,061
-1,100
-51% -$6.81K ﹤0.01% 1391
2021
Q2 		$14K Buy
2,161
+1,800
+499% +$15K ﹤0.01% 1272
2021
Q1 		$3K Buy
+361
New +$3.95K ﹤0.01% 1333
2018
Q2 		– Sell
-2,861
Closed -$63K – 1575
2018
Q1 		$63K Buy
+2,861
New +$63.5K 0.01% 947

Other funds holding JNCE

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Quantbot Technologies's JNCE Position: Q1 2022 in Review

Quantbot Technologies sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2022, closing a stake of 561 shares — an estimated $4K sold.

Quantbot Technologies first reported a position in JNCE in Q1 2018 and held it in 5 quarters. The position peaked at $63K in Q1 2018. 113 funds tracked by Wall St. Rank hold JNCE as of Q1 2022.

  • Quantbot Technologies reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Quantbot Technologies sold 561 Jounce Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $4K.
  • Quantbot Technologies first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2018 and held it in 5 quarters.
  • Quantbot Technologies's Jounce Therapeutics, Inc. Common Stock position peaked at $63K in Q1 2018.
  • 113 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Quantbot Technologies's 13F filing for Q1 2022, filed 16 May 2022.